A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy

2023176 citationsJournal Articlegreen Open Access

Authors

Mohit Mathur · Visterra (United States)

Jonathan Barratt · Leicester General Hospital

Bobby Chacko · John Hunter Hospital

Tak Mao Chan · Queen Mary Hospital

Laura Kooienga · Colorado Kidney Care

Kook‐Hwan Oh · Seoul National University

Manisha Sahay ·

Abstract

In patients with IgA nephropathy, 12 months of treatment with sibeprenlimab resulted in a significantly greater decrease in proteinuria than placebo. (Funded by Visterra; ENVISION ClinicalTrials.gov number, NCT04287985; EudraCT number, 2019-002531-29.).

Topics & Keywords

Renal Diseases and Glomerulopathies Platelet Disorders and Treatments Chronic Lymphocytic Leukemia Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 390, Issue 1, pp. 20-31

DOI: 10.1056/nejmoa2305635

Field-Weighted Citation Impact: 34.58